ALKS

NEUTRALProduct

Alkermes plc

2026-07-10

Price

$51.94

-3.42%

This is the 2026-07-10 snapshot — the signals and analysis for ALKS as of this single trading day.

View full ALKS research hub →

Score2.8Noise

Signals2/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 7

Volume0.6xvs 20d avg

Analysis

Alkermes is demonstrating textbook institutional absorption, shrugging off a hawkish Fed and geopolitical turmoil to maintain a powerful multi-month uptrend. The stock's PERFECT_STACK and GOLDEN_CROSS signals are fundamentally anchored by positive Phase 2 Vibrance-2 data for its narcolepsy drug and a recent inclusion in the Russell 2000 Dynamic Index. In a RISK_ON regime where the broader market is ignoring macro headwinds, ALKS's idiosyncratic catalysts and robust relative strength warrant a high-conviction bullish stance on this minor pullback.

Fired Signals

GOLDEN CROSSPERFECT STACKBARGAIN HUNTER

Key Takeaways

Actionable Thesis: Buy the current low-volume dip to capitalize on the Golden Cross and ongoing institutional flows from the recent Russell 2000 index inclusion [1.2.6].
Key Risk: Elevated valuation metrics and recent insider selling of $2.2M over the last 3 months could cap upside if momentum stalls.
What to Watch: Monitor the $44.09 structural support level and look ahead to the Q2 earnings report on July 28, 2026, for fundamental validation.

← Back to 2026-07-10 View Full ALKS History →Yahoo Finance &nearr;